1477 Stock Overview
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ocumension Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.19 |
| 52 Week High | HK$7.54 |
| 52 Week Low | HK$4.13 |
| Beta | 0.80 |
| 11 Month Change | -8.95% |
| 3 Month Change | -2.99% |
| 1 Year Change | -28.02% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1477 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.8% | 0.07% | -0.6% |
| 1Y | -28.0% | -10.2% | 9.6% |
Return vs Industry: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 1477 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 1477 volatility | |
|---|---|
| 1477 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1477 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1477's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 477 | Victor Liu | www.ocumension.com |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.
Ocumension Therapeutics Fundamentals Summary
| 1477 fundamental statistics | |
|---|---|
| Market cap | HK$4.24b |
| Earnings (TTM) | -HK$346.72m |
| Revenue (TTM) | HK$333.37m |
12.7x
P/S Ratio-12.2x
P/E RatioIs 1477 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1477 income statement (TTM) | |
|---|---|
| Revenue | CN¥310.29m |
| Cost of Revenue | CN¥129.44m |
| Gross Profit | CN¥180.86m |
| Other Expenses | CN¥503.58m |
| Earnings | -CN¥322.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 58.29% |
| Net Profit Margin | -104.01% |
| Debt/Equity Ratio | 0% |
How did 1477 perform over the long term?
See historical performance and comparison